hotspot -WSS

hotspot

author：leisure time 2025-10-01 23:07:13 - browse：276

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Biden's 'march

WSS

Lack of health data on LGBTQ+ people has serious consequences

STAT Summit: GSK CEO on pharma giant's new direction

Researchers explore possible ties between long Covid, menopause

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

UnitedHealth’s board chair also owns a personal investment firm

2023 STAT Wunderkinds: get to know the winners

Wikipedia

hotspot

leisure time

How one medical school became remarkably diverse

Microsoft's Peter Lee: Generative AI could help doctors be more human

Affirmative action in medical school literally saved lives

The untold story of TV’s first prescription drug ad

DIEP, the 'gold standard' of breast reconstruction, is under threat

Stem cell biologist probes earliest stages of human development

New air purifier tech could be key to improving indoor air quality

HHS leader on health, climate change and biopharma emissions

United colonoscopy coverage change 'may cost lives,' doctors say

Lawmakers consider Medicare pay reforms for doctors

focus

Longer MASH drug regimen improved liver, Akero study finds

2023 STAT Wunderkinds: get to know the winners

For AI in health care standards, federal regulators join with industry group

STAT Summit: Biotech founders on deal

Hospital price transparency does save money, advocate argues

HHS leader on health, climate change and biopharma emissions

hotspot

explore

knowledge

focus